A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
← catalyst calendarNCT06823167 · readout ≤ 650 d
Sponsored by Immunome, Inc. (industry) · IMNM — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
190estimated
Sites
24
Countries
Denmark, France, Spain +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-26 | actual | When the study began enrolling |
| Primary completion | May 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Malignancies
- Hematologic Malignancies
Intervention
- Drug: IM-1021
Primary outcomes
what the primary-completion date above is the date OFSafety and tolerability of IM-1021 in participants with advanced lymphomas and advanced solid tumors as measured by incidence of treatment emergent adverse events (TEAEs)
measured From first dose to 37 days following last dose of study treatment
Determine the recommended dose(s) and schedule(s) of IM-1021 for further development
measured From first dose to 37 days following last dose of study treatment
Permalink · IMNM's whole pipeline · Catalyst calendar · Every registered study · What changed